About the Company
Biochemical Pharmaceutical Co., Ltd. Changzhou Benny (stock abbreviation: "Benny Pharmaceuticals", stock code: 002550) was established in March 15, 2008, the predecessor was founded in 1971, Changzhou plant biochemistry, February 18, 2011 In small plates listed on the Shenzhen Stock Exchange.
National High-Tech Development Zone is located in Changzhou City, Jiangsu Province, is a national high-tech enterprise, knowledge-int...
Biochemical Pharmaceutical Co., Ltd. Changzhou Benny (stock abbreviation: "Benny Pharmaceuticals", stock code: 002550) was established in March 15, 2008, the predecessor was founded in 1971, Changzhou plant biochemistry, February 18, 2011 In small plates listed on the Shenzhen Stock Exchange.
National High-Tech Development Zone is located in Changzhou City, Jiangsu Province, is a national high-tech enterprise, knowledge-intensive and technology-intensive enterprises in Jiangsu Province, the country "a new high-tech products enzymes industrialization demonstration project" and the state "three-drug base" key enterprise, quality heparin and pancreatic kallikrein large variety of biochemical drugs by Jiangsu Provincial Science and Technology Department identified as "major technological innovation and industrial transformation project"; biologics targeting a class of antithrombotic recombinant human protein (rHAP) genetic engineering and targeting anticancer drugs (TRAIL), was included in the National Science and Technology "National Key New Drug Creation Project", which rHAP has completed preclinical studies, clinical studies are being reported; owns four holding subsidiaries, including Changzhou Biopharmaceutical Engineering Technology Center Co., Ltd. and Changzhou Benny Universal Cell Engineering Institute Co., Ltd. is mainly engaged in natural medicine, genetic engineering and other aspects of research and development; Hubei Run Red Biotechnology Co., Ltd., is mainly engaged in heparin raw materials, casings production and sales; Jiangsu congregation red Biological Engineering Co., Ltd. Drug Discovery Institute, focused on the development of international leading level gene drugs.
All products are manufactured by China's pharmaceutical GMP quality certification, which exports raw materials and bulk drugs heparin, a small molecule heparin, asparaginase APIs also passed the U.S. FDA, EEC COS, Australia TGA, Japan, related quality of Germany, South Korea and Brazil and other countries of the certification. The main production technology and quality of products has reached international standards, domestic leading level. Meanwhile, the company adhere to independent research and sustainable development model combining research cooperation, and establish a good working relationship with the major institutions of higher learning. Currently, the company developed the technology platform promoted to provincial engineering technology centers, and as a platform as the basis, the modern molecular ultrafiltration membranes, protein affinity chromatography, molecular chelation, viral inactivation techniques applied to large-scale integrated industrial production, and achieved remarkable results. August 2012, the company was approved by the Ministry of Science as "Benny Changzhou international biomedical incubator of innovative drugs", initially formed a joint venture Institute, R & D team and technical team for the development of integrated echelon system.
Through years of marketing practices in the biopharmaceutical field to get a good position in the market. In urban areas of the country with the major developed countries with GSP certification qualifications of more than thirty pharmaceutical marketing company to establish a stable and cooperative relations, and has more than twenty provinces and cities in the country to establish a regional marketing offices, forming a support professional marketing team and better marketing network. Some products are exported to Germany, Italy, USA, Japan, Korea, India and Brazil and other countries.
With the successful listing of the company, the company will use the platform and the effect of good capital markets, and growth creates a good foundation for the future development of the company. The company will use the proceeds to complete the construction company's main business expansion projects and the completion of a joint Institute of Biomedicine international level - all red, Jiangsu Institute of Biological Engineering Co., Ltd. Chong medicine, committed to the development of international leading level of gene drugs to achieve Gorgeous genetic engineering drugs to turn from the natural medicine for the future health of the company, sustained and rapid development has laid a good foundation for a strategic win-induced high point of the company's strategic development. The company will actively explore and proceed to extend the industrial chain integration, integration of upstream raw material resources in the form of joint venture equity participation; downstream through the building in line with European standards preparation plant, increase the added value of products, enrich and improve the company's industrial chain and increase the industry's competitiveness.
Looking ahead, the company will strive to expand the two major areas of biomedical industry and medical health industry. In the biomedical industry, the company will uphold the "good intentions medicine, for the benefit of all mankind," the noble mission and "safer, more effective, more economical," business philosophy, to establish a scientific, perfect quality prevention, control systems and innovation R & D system, and enhance core competitiveness; continue to introduce high-quality talents applicable, increase drug marketing teams and team building development; actively participate in domestic and international competition and cooperation in the pharmaceutical market, and strive to become a major domestic and international competitive bio-medicine one of the enterprises. In the medical health industry, the company will actively explore the development strategy for the company on the road, exploring appropriate resources, and strive success rate of investment projects, and through this platform to make a useful contribution of private capital for the regional and national social programs.
Market Place
